Search clinical trials for: PD-1 antibody expressing mesothelin specific CAR-T cells

Total 262 results

Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Advanced Cancer | Solid Tumor, Adult

China
Seattle Children's Hospital
The Evan Foundation; Ben Towne Center for Childhood Cancer Research

Active, not recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Neuroblastoma | Ganglioneuroblastoma

United States
Cancer Institute and Hospital, Chinese Academy...
UTC Therapeutics Inc.

Not yet recruiting

MSLN-targeted CAR-T Cells in Solid Tumors.

Mesothelin-positive Advanced Malignant Solid Tumors
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
Shanghai Cell Therapy Research Institute

Unknown

PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST)

Advanced Solid Tumor

China
Seattle Children's Hospital

Active, not recruiting

A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Recurrent Mantle Cell Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Refractory Chronic Lymphocytic Leukemia | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Acute Lymphoblastic Leukemia | Metastatic Triple-Negative... and other conditions

United States
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
Zhejiang University
UTC Therapeutics Inc.

Recruiting

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
AlloVir
Baylor College of Medicine; The Methodist Hospital Research Institute; Center...

Completed

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus (ARMS)

Viral Infection

United States
Beijing 302 Hospital
Tsinghua University

Unknown

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection (TCTIWHI)

HIV-1

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal CAR-T Cells Targeting AML

Acute Myeloid Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Seattle Children's Hospital

Active, not recruiting

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

CD19+ Acute Leukemia

United States
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Mesothelin Positive Tumors

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Glioblastoma | Ependymoma | Medulloblastoma | Recurrent Metastatic Malignant Neoplasm in the Leptomeninges

United States
Chinese PLA General Hospital

Unknown

Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors

Solid Tumor, Adult

China
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Sichuan University

Not yet recruiting

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

Neuroblastoma

United States
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Acute Myeloid Leukemia

United States

Search clinical trials for: PD-1 antibody expressing mesothelin specific CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations